Zu lab Publications


Precision Molecular Pathology of Myeloid Neoplasms: Updates in Polycythemia Vera
Zu, Y & Olsen, RJ 2018, . in C-CJ Chang & R Ohgami (eds), Precision Molecular Pathology of Myeloid Neoplasms: Updates in Polycythemia Vera. 1st edn, vol. 12, Springer, Switzerland, pp. 115-139. DOI: 10.1007/978-3-319-62146-3

A novel DNA aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells
Liu, H, Mai, J, Shen, J, Wolfram, J, Li, Z, Zhang, G, Xu, R, Li, Y, Mu, C, Zu, Y, Li, X, Lokesh, GL, Thiviyanathan, V, Volk, DE, Gorenstein, DG, Ferrari, M, Hu, Z & Shen, H 2018, Theranostics, vol 8, no. 1, pp. 31-44. DOI: 10.7150/thno.21342

Spin-Valve based magnetoresistive nanoparticle detector for applications in biosensing
Qiu, W, Chang, L, Liang, YC, Litvinov, J, Guo, J, Chen, YT, Vu, B, Kourentzi, K, Xu, S, Lee, TR, Zu, Y, Willson, RC & Litvinov, D 2017, Sensors and Actuators, A: Physical, vol 265, pp. 174-180. DOI: 10.1016/j.sna.2017.08.018


Ultrasensitive magnetic nanoparticle detector for biosensor applications
Liang, YC, Chang, L, Qiu, W, Kolhatkar, AG, Vu, B, Kourentzi, K, Lee, TR, Zu, Y, Willson, R & Litvinov, D 2017, Sensors (Switzerland), vol 17, no. 6, 1296. DOI: 10.3390/s17061296

Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy
Li, H, Yang, S, Yu, G, Shen, L, Fan, J, Xu, L, Zhang, H, Zhao, N, Zeng, Z, Hu, T, Wen, J & Zu, Y 2017, Theranostics, vol 7, no. 5, pp. 1204-1213. DOI: 10.7150/thno.17069

B7-H4 expression in ovarian serous carcinoma: a study of 306 cases
Liang, L, Jiang, Y, Chen, JS, Niu, N, Piao, J, Ning, J, Zu, Y, Zhang, J & Liu, J 2016, Human Pathology, vol 57, pp. 1-6. DOI: 10.1016/j.humpath.2016.06.011

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
Xia, Y, Xu-Monette, ZY, Tzankov, A, Li, X, Manyam, GC, Murty, V, Bhagat, G, Zhang, S, Pasqualucci, L, Visco, C, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Westin, J, Fowler, N, Miranda, RN, Ok, CY, Li, Y, Li, J, Medeiros, LJ & Young, KH 2016, Leukemia. DOI: 10.1038/leu.2016.243

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Chen, Z, Shao, C, Wang, W, Zuo, Z, Mou, X, Hu, SJ, DiGiuseppe, JA, Zu, Y, Medeiros, LJ & Hu, S 2016, Leukemia. DOI: 10.1038/leu.2016.231

Overt leukemic phase: an unusual presentation of angioimmunoblastic lymphoma
Arora, K, Zhang, L, Xie, W, Baker, KR, Zu, Y & Hao, S 2016, Journal of Hematopathology, vol 9, no. 3, pp. 139-142. DOI: 10.1007/s12308-016-0278-3

Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma
Xu-Monette, ZY, Deng, Q, Manyam, GC, Tzankov, A, Li, L, Xia, Y, Wang, XX, Zou, D, Visco, C, Dybkær, K, Li, J, Zhang, L, Liang, H, Montes-Moreno, S, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Wang, SA, Miranda, RN, Piris, MA, Winter, JN, Medeiros, LJ, Li, Y & Young, KH 2016, Clinical Cancer Research, vol 22, no. 14, pp. 3593-3605. DOI: 10.1158/1078-0432.CCR-15-2296

Aptamers: Versatile molecular recognition probes for cancer detection
Sun, H, Tan, W & Zu, Y 2016, Analyst, vol 141, no. 2, pp. 403-415. DOI: 10.1039/c5an01995h

RelA NF-kB subunit activation as a therapeutic target in diffuse large B-cell lymphoma
Zhang, M, Xu-Monette, ZY, Li, L, Manyam, GC, Visco, C, Tzankov, A, Wang, J, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Medeiros, LJ, Pham, LV & Young, KH 2016, Aging, vol 8, no. 12, pp. 3321-3340. DOI: 10.18632/aging.101121

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
Ye, Q, Xu-Monette, ZY, Tzankov, A, Deng, L, Wang, X, Manyam, GC, Visco, C, Montes-Moreno, S, Zhang, L, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Piris, MA, Winter, JN, Medeiros, LJ, Hu, VDS & Young, KH 2016, Oncotarget, vol 7, no. 3, pp. 2401-2416. DOI: 10.18632/oncotarget.6262

p63 expression confers significantly better survival outcomes in highrisk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function
Xu-Monette, ZY, Zhang, S, Li, X, Manyam, GC, Wang, XX, Xia, Y, Visco, C, Tzankov, A, Zhang, L, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, HJ, Huh, J, Ponzoni, M, Ferreri, AJM, Zhao, X, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Medeiros, JL & Young, KH 2016, Aging, vol 8, no. 2, pp. 345-365.

SsDNA aptamer specifically targets and selectively delivers cytotoxic drug doxorubicin to HepG2 Cells
Yu, G, Li, H, Yang, S, Wen, J, Niu, J & Zu, Y 2016, PLoS ONE, vol 11, no. 1, e0147674. DOI: 10.1371/journal.pone.0147674

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Xu-Monette, ZY, Dabaja, BS, Wang, X, Tu, M, Manyam, GC, Tzankov, A, Xia, Y, Zhang, L, Sun, R, Visco, C, Dybkaer, K, Yin, L, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Zhao, X, Winter, JN, Piris, MA, McDonnell, TJ, Miranda, RN, Li, Y, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 12, pp. 1555-1573. DOI: 10.1038/modpathol.2015.118

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy
Liu, Z, Xu-Monette, ZY, Cao, X, Manyam, GC, Wang, X, Tzankov, A, Xia, Y, Li, X, Visco, C, Sun, R, Zhang, L, Montes-Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Piris, MA, Winter, JN, OMalley, DP, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 10, pp. 1297-1314. DOI: 10.1038/modpathol.2015.94

Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia
Zhao, N, Pei, SN, Qi, J, Zeng, Z, Iyer, SP, Lin, P, Tung, CH & Zu, Y 2015, Biomaterials, vol 67, pp. 42-51. DOI: 10.1016/j.biomaterials.2015.07.025

Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions
Ok, CY, Xu-Monette, ZY, Li, L, Manyam, GC, Montes-Moreno, S, Tzankov, A, Visco, C, Dybkær, K, Routbort, MJ, Zhang, L, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Rao, H, Møller, MB, Winter, JN, Piris, MA, Wang, SA, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 9, pp. 1202-1213. DOI: 10.1038/modpathol.2015.76